June Beaker go-live updates. Billing and compliance. Chemistry. Drug screen testing. Referral Testing. Website
|
|
- Aleesha Paul
- 5 years ago
- Views:
Transcription
1 June 2014 Beaker go-live updates Blood Bank and Referral Testing (SendOuts) Anatomic pathology go-live rescheduled Billing and compliance Referral testing pricing changes Chemistry New HIV testing algorithm Drug screen testing Urine drug screen test menu revised Referral Testing New orderable tests Website Test catalog updates in progress
2 BEAKER GO-LIVE UDPATES Blood Bank and Referral Testing live on Beaker On June 13th, the Allina Health Laboratory Blood Bank and Referral Testing (SendOuts) departments went live on the new Beaker LIS. With the Referral Testing go-live, several new tests were made orderable, and no longer require use of the LAB994 generic test code. A list of the affected tests is included in the referral testing section. What does this mean for you? Clients using Excellian and Ultra/Beaker You should be receiving Beaker labels, rather than Ultra labels, for Blood Bank testing along with any tests referred out to other testing laboratories. Only the AP departments (Cytology, Cytogenetics, Flow Cytometry, Histology and Molecular Diagnostics) and select clinical testing (Peripheral Morphology, Bone Marrows and Kleihauer Stains) will remain in Ultra. Follow the Beaker processes for the specimens generating Beaker labels, and continue to follow current processes for the testing that remains in Ultra. Clients ordering using manual requisitions Reports for blood bank and referral tests will now appear in the new Beaker report format. Only the AP departments (Cytology, Cytogenetics, Flow Cytometry, Histology and Molecular Diagnostics) and select clinical testing (Peripheral Morphology, Bone Marrows and Kleihauer Stains) testing will remain in Ultra and report in the Ultra format. Examples of Beaker reports can be viewed on our website at allinahealth.org/laboratory. Anatomic pathology go-live rescheduled In order to allow sufficient time for thorough testing and validation of the new system prior to implementation, Allina Health has made the decision to reschedule the Central Laboratory Anatomic Pathology (AP) Beaker go live to Friday August 1st. Departments affected by this include; Cytogenetics, Cytology, Flow Cytometry, Histology and Molecular Diagnostics. In addition to this, the Bone Marrow and Peripheral Blood Morphology tests will also transition to Beaker on August 1st. 2
3 BILLING AND COMPLIANCE Referral Testing performing laboratory and pricing changes As a part of our Referral Testing laboratory transition to our new LIS, Beaker, that occurred on May 30th, several tests have been changed to now go to, or through, Mayo Medical Laboratories (MML). Our test catalog has been updated to reflect this information. Test Name: Chlamydia pneumoniae DNA PCR Test Code: LAB2467 [ ] (MML: FCPD) CPT: List Price: $ Test Name: 68 KD (HSP-70) Antibody Test Code: LAB5519 [ ] (MML: F68KD) CPT: List Price $ Test Name: Plasminogen Chromogenic Test Code: LAB994 (MML: PSGN) CPT: List Price $47.20 Test Name: T3, Reverse Test Code: LAB123/T3R [ ] (MML: RT3) CPT: List Price: $32.30 We have received notice of a fee change for the Polio Immune Status Assay (LAB816) referred to Focus Diagnostics via Mayo Medical Laboratories, effective June 19th. The fee for this assay decreased from $ to $ Test Name: Polio Immune Status Test Number: LAB816 Performing Lab: Focus via Mayo Medical Labs (FPOLS/91469); R-MM CPT Codes: x 3 Old Fee: $ New Fee: $
4 Allina Health Laboratory has also received notice from the University of MN Physicians Outreach Laboratory of fee changes which are effective July 1, The affected tests, along with the CPT codes, current and new pricing, are listed below. Panel Name Order Code LAB # Alternate Name Current Price NEW Price (Eff. 7/1/14) Activated Protein C Resistance APC $49.70 $ Anti-Leukocyte Antibodies PRA $ $ ***HLA ABY Class I $ $ ***HLA ABY Class II $ $ Cyclosporin A UCY $36.70 $ HLA ABC Typing LAB HLA $ $ LS Ratio, PG and DSL LAB (Reflex for Lamellar Body Count) FL3 $ $ ***L/S Ratio $96.00 $ ***Phosphatydl Glycerol $75.50 $ ***DSL $ $ Rapamycin RAP $45.30 $ Tacrolimus F50 $55.00 $ CPT 4
5 CHEMISTY HIV 1/2 antigen/antibody combo & HIV differentiation test algorithm On April 12, 2014 Allina Health Laboratory converted to a new testing algorithm for the diagnosis of HIV infection. The new algorithm meets the new Draft Recommendations as proposed by the Centers for Disease Control which have been shown to improve detection of acute HIV infection (first three months), a period when patients have high circulating levels of virus and are highly infectious. The new algorithm begins with the Abbott Architect HIV Ag/Ab Combo 4th generation immunoassay. This is an FDA-approved assay which detects circulating IgM and IgG antibodies to both HIV-1 and to HIV-2, and also detects antibodies to the p24 antigen. This screening immunoassay produces a positive result if antibodies to any of the three tested components (HIV-1, HIV-2 or p24 antigen) are present, but does not differentiate between them, so a positive result for any of the three tested components is followed by a confirmatory BioRad Multi-spot HIV-1/HIV-2 differentiation immunoassay. Possible results are outlined in graphic form (from the CDC Draft Recommendations) below along with commentary from the CDC regarding interpretation of results (#1-5). This is followed by a more detailed summary of Allina Health Laboratory reported results. 5
6 1. An FDA-approved 4th generation HIV-1/2 immunoassay (IA) should be used as the initial test, to screen for acute HIV-1 infection and for established infections with HIV-1 or HIV Specimens with a reactive 4th generation IA (or repeatedly reactive, if repeat testing is recommended by the manufacturer) should be tested with an FDA-approved 2nd generation antibody IA that differentiates HIV-1 antibodies from HIV-2 antibodies. 3. Persons whose specimens give positive results on the initial IA and HIV-1/HIV-2 antibody differentiation IA should be considered positive for HIV-1 or HIV-2 antibodies and should initiate medical care that includes laboratory tests (such as viral load, CD4 determinations, and antiretroviral resistance assays) to confirm the presence of HIV infection, to stage HIV disease, and to assist in the selection of an initial antiretroviral drug regimen. [DHHS Guidelines] 4. Specimens that are reactive on the initial assay and negative on the HIV-1/HIV-2 antibody differentiation IA should be tested with an FDA-approved nucleic acid test (NAT) for HIV-1 RNA. Under these circumstances, a reactive NAT result indicates the presence of acute HIV-1 infection. A negative result indicates the absence of HIV-1 infection, either a falsepositive result on the initial IA or rarely, recent HIV-2 infection. If HIV-2 infection is a possibility, a NAT for HIV-2 DNA can be considered. However, HIV-2 infection is rare in the United States, and there is no FDA-approved NAT for HIV This same testing algorithm beginning with a 4th generation immunoassay should be followed for specimens from persons with a preliminary positive rapid HIV test result. Summary of Allina Health Laboratory testing algorithm: Architect HIV Ag/Ab Combo Assay Result: Negative, no evidence of HIV infection based on clinical information Re-test Architect HIV Ag/Ab Combo Assay result: Positive differentiation Assay reflex to BioRad Multi-spot HIV-1/HIV-2 6
7 HIV-1/HIV-2 Differentiation assay results: HIV-1 HIV-2 Interpretation Positive Non-reactive Positive for HIV-1 Antibodies. Suggest follow-up testing: HIV-1 RNA Quant (HVL) Non-reactive Positive Positive for HIV-2 Antibodies. Suggest follow-up testing: HIV-2 DNA (Mayo) Non-reactive Non-reactive HIV Ag/Ab combo test is positive, presumably due to presence of HIV p24 Ag, non-reactive for both HIV-1 and HIV-2 antibodies, Suggest follow-up testing: HIV-1 RNA Quant (HVL) Indeterminate Indeterminate HIV Ag/Ab combo test is positive, possibly due to presence of HIV p24 Ag as differentiation assay is indeterminate for both HIV-1 and HIV-2 antibodies, Suggest follow-up testing: HIV-1 RNA Quant (HVL) Indeterminate Positive Indeterminate for HIV-1 and positive for HIV-2, Suggest follow-up testing: HIV-1 RNA Quant (HVL), HIV-2 DNA (Mayo) Positive Indeterminate Indeterminate for HIV-2 and positive for HIV-1, Suggest follow-up testing: HIV-1 RNA Quant (HVL) Positive Positive HIV positive but undifferentiated, additional testing recommended Suggest follow-up testing: HIV-1 RNA Quant (HVL) Positive for HIV-2 Antibodies, HIV-2 DNA (Mayo) 7
8 URINE DRUG SCREENING Urine drug screen test menu revised To better address the complexities of drug screening for different patient groups, Allina Health Laboratory has revised the urine drug screen test menu. This information does not include maternal/infant drug screening, which has separate requirements. The revised test menu consists of 4 drug screen panels: 1. Urine drugs of abuse presumptive screen, LAB597. A preliminary screen with limited clinical utility. 2. Limited Compliance Drug Monitor, LAB NEW - Optimized for monitoring patients in chemical dependency programs. 3. Comprehensive Compliance Drug Monitor, LAB8742. Comprehensive drug screen. Preferred test for monitoring patients in pain management programs. 4. Synthetic cannabinoids qualitative screen, LAB Detects bath salts, K2, Spice. Important: Drug screening at Allina Health Laboratory cannot be used for any legal purpose, with the exception of certain maternal/infant specimens that are collected through special procedures. The following information includes comparison charts, lists of drugs detected, and sample reports. Urine drugs of abuse presumptive screen, LAB597 - turnaround time stat (1 hour from arrival in lab) or routine (same day). Allina Health Laboratory receives many questions about the reliability and interpretation of this drug screen. This drug screen provides only a preliminary presumptive result and has limited clinical utility. Due to many cross reactions inherent in the rapid screen technology, this screen is not preferred for chemical dependency or pain management monitoring. When this test is ordered, consideration and professional judgment must be applied in evaluating a preliminary positive result. Confirmation testing should be ordered on any unexpected presumptive positive result; it is important to understand that many of these results will NOT confirm on further analysis by chromatography and mass spectrometry. For example, only 40-50% of screening positives for opiates or amphetamines will confirm. Important points to remember about this drug screen (and all rapid presumptive drug screens and cup tests): 1. This screen cannot distinguish between abused drugs and many common prescribed and over-the-counter medications. 2. Certain foods or legitimate medications may interfere with screening tests and cause false positive results. 3. It is not possible to predict all interferences and false positive reactions because of individual differences in medications, drug metabolism, and diet. 8
9 4. The number of screening positives that confirm on further testing is as low as 40%, depending on the drug and patient population. Do not assume that a presumptive positive result is real. Order confirmation testing if the result is unexpected. Limited Compliance Drug Screen, LAB 12507, *NEW* - turnaround time 3-5 days. This screen is the preferred test for monitoring patients in chemical dependency programs. The screen includes alcohol metabolites and important drugs of abuse. Confirmations are automatically performed for positives except for THC (a separate order would be required if confirmation is needed.) Comprehensive Compliance Drug Monitor, LAB turnaround time 5-7 days. This screen is comprehensive and preferred for monitoring patients in pain management programs and other medical indications for nonemergency comprehensive screening. Results are definitive and confirmed. The screen includes over 170 drugs in 22 classes. Quantitative results (normalized to creatinine) are reported for many drugs. Synthetic Cannabinoid (K2, Spice, bath salts) Qualitative Screen, LAB turnaround time 5-7 days. Synthetic cannabinoids such as K2, Spice, and bath salts require special technology for detection and are not included in the other screening panels. 9
10 ALLINA HEALTH LABORATORY - REVISED URINE DRUG SCREENING TEST MENU TAT Performing laboratory Description Automatic confirmations In-House Rapid Presumptive Screen LAB597 presumptive screen only ROUTINE (same day) or STAT (1 hour from receipt in laboratory) Limited Compliance Screen *NEW* LAB12507 for monitoring chemical dependency patients ROUTINE only. Cannot order stat. 3-5 days. Comprehensive Drug Screen & Compliance Monitor LAB8742 (aka ToxAssure or Med- Watch) Pain compliance and nonemergency comprehensive drug screening ROUTINE only. Cannot order stat. 5-7 days Synthetic Cannabinoid Qualitative Screen LAB12396 K2, Spice, "bath salts" ROUTINE only. Cannot order stat. 3-5 days. Allina Health Laboratory MedTox MedTox MedTox Clinical utility is limited. Should be ordered only by providers who understand the limitations of antibodybased drug screens. Positive results must be interpreted with caution. Screening results are preliminary only; many screening positives will NOT confirm on further testing. Confirmation testing should be ordered for any unexpected positive (or negative) results. NONE. Confirmations are NOT automatically performed and must be ordered separately. 5-7 day turnaround time for confirmations. Routine screening of patients in the chemical dependency program. Included and automatically performed, except THC. (Confirmation for THC must be specifically ordered if needed.) Routine comprehensive drug screening for compliance monitoring in pain management or other medical indications where comprehensive screening is needed. Unnecessary, results are comprehensive and definitive. Detection of synthetic cannabinoids Results are confirmed. Reporting Qualitative results (presumptive positive/ not detected) Qualitative results (positive/negative). Qualitative (pos/neg) and Quantitative (value normalized to creatinine for many drugs) Qualitative. (For quantitative results, order LAB12521) 10
11 COMPARISON CHART: GENERAL DRUG SCREEN PANELS AVAILABLE FROM ALLINA HEALTH LABORATORY Drugs of Abuse LAB597 NEW Limited Compliance Screen LAB12507 Comprehensive Compliance Drug Screen (ToxAssure) LAB8742 DRUG DETECTION THRESHHOLD (ng/ml) DRUG CLASS DRUGS REPORTED Ethyl Glucuronide Not included 250 *Opiates: codeine, hydrocodone, hydromorphone, morphine, dihydrocodeine Etheyl Sulfate Not included 100 *Oxycodones: oxycodone, oxymorphone Amphetamines *Buprenorphine: buprenorphine, norbuprenorphine Methamphetamine 500 No separate test, metabolizes to amphetamine *Methadone: methadone, EDDP Barbiturates *Amphetamines: methamphetamine, amphetamine, methylenedioxymethamphetamine (MDMA), methylenedioxyamphetamine (MDA), methylenedioxyethylamphetamine (MDEA) Benzodiazepines *Cocaine MTB: cocaine, benzoylecgonine, cocaethylene Cocaine Metabolite *Benzodiazepines: Fentanyl Not included 1 "Opiates" includes: Other Hallucinogens: *Cannabinoids/ THC: Codeine Antidepressants: Morphine Barbiturates: alprazolam, alpha-hydroxyalprazolam, chlordiazepoxide (as metabolites), clonazepam, 7-aminoclonazepam, clorazepate (as metabolite), desalkylflurazepam, diazepam, desmethyldiazepam, lorazepam, midazolam, oxazepam, temazepam, alpha-hydroxytriazolam ketamine, phencyclidine Heroin *Ethyl Alcohol: ethyl alcohol 9 -carboxy-tetrahydrocannabinol (carboxy-thc) amitriptyline, amoxapine, 8- hydroxyamoxapine,bupropion, citalopram, desmethylcitalopram, escitalopram, clomipramine, desmethylclomipramine, desipramine, desvenlafaxine, doxepin, desmethyldoxepin, duloxetine, fluoxetine, norfluoxetine, fluvoxamine, imipramine, maprotiline, mirtazapine, nefazodone, nortriptyline, protriptyline, sertraline, desmethylsertraline, trazodone, trimipramine, venlafaxine, desmethylvenlafaxine amobarbital, barbital, butabarbital, butalbital, mephobarbital, pentobarbital, phenobarbital, secobarbital, thiopental 11
12 Drugs of Abuse Limited Compliance Screen Comprehensive Compliance Drug Screen (ToxAssure) LAB8742 DRUG DETECTION THRESH- DRUG CLASS DRUGS REPORTED Hydrocodone Sympathomimetics: ephedrine, methcathinone, methylphenidate, phenmetrazine, phentermine, phenylpropanolamine, pseudoephedrine Hydromorphone *Fentanyl and Analogs: fentanyl, norfentanyl, sufentanil, alfentanil Dihydrocodeine *Other Opiodes: butorphanol, levorphanol, meperidine, normeperidine, nalbuphine, naltrexone, pentazocine, propoxyphene, norpropoxyphene, tapentadol, tramadol, O- desmethyltramadol, N- desmethyltramadol, 6MAM (Heroin-Specific) Not included 10 Anticonvulsants: carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine MHD, phenytoin, pregabalin, primidone, rufinamide, tiagabine, topiramate, zonisamide Oxycodone Muscle Relaxants: PCP (Phencyclidine) 25 Not included Other Sedative/ Hypnotics: THC Metabolite Antidepressants: Methadone Antipsychotics: baclofen, carisoprodol, cyclobenzaprine, meprobamate, metaxolone, methocarbamol, orphenadrine, tizanidine eszopiclone, zaleplon, zopiclone, zolpidem amitriptyline, amoxapine, 8- hydroxyamoxapine,bupropion, citalopram, desmethylcitalopram, escitalopram, clomipramine, desmethylclomipramine, desipramine, desvenlafaxine, doxepin, desmethyldoxepin, duloxetine, fluoxetine, norfluoxetine, fluvoxamine, imipramine, maprotiline, mirtazapine, nefazodone, nortriptyline, protriptyline, sertraline, desmethylsertraline, trazodone, trimipramine, venlafaxine, desmethylvenlafaxine aripiprazole, chlorpromazine, clozapine, norclozapine, fluphenazine, haloperidol, loxapine, 8- hydroxyloxapine, mesoridazine, molindone, olanzapine, perphenazine, pimozide, prochlorperazine, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, ziprasidone 12
13 DRUG Drugs of Abuse LAB597 Limited Compliance Screen LAB12507 DETECTION THRESHHOLD (ng/ml) Comprehensive Compliance Drug Screen (ToxAssure) LAB8742 DRUG CLASS Propoxyphene Not included 300 Analgesics/NSAIDS Buprenophine 10 5 Antihistamines: Tramadol Not included 200 Local Anesthetics: Miscellaneous: DRUGS REPORTED acetaminophen, ibuprofen, ketoprofen, naproxen, oxaprozin, salicylate brompheniramine, chlorpheniramine, diphenhydramine, doxylamine, hydroxyzine, promethazine, pyrilamine, triprolidine bupivacaine, lidocaine, mepivacaine, procaine atenolol, benztropine, caffeine (large amounts), clonidine, dextromethorphan, dextrorphan, diltiazem, guaifenesin, metoprolol, propranolol, theophylline, verapamil 13
14 14
15 15
16 16
17 17
18 18
19 19
20 20
21 REFERRAL TESTING New orderable tests With the transition of our Referral Testing department to our new LIS, Beaker, a group of tests previously requiring use of our generic ordering code (994/MSO) were made orderable with unique codes. The Allina Health Laboratory test catalog has been updated with this information, and the manual requests forms are also being updated. As additional tests are built with ordering codes in the Beaker system, further communication will be shared. Performing Lab Performing Lab Code NEW AHL Ordering Code Test Name Mayo AMH LAB12474 Antimullerian Hormone (AMH), Serum Mayo AVOC LAB12498 Avocado, IgE MedTox LAB12519 Barium, Blood MedTox LAB12517 Chromium, 24 Hr Urine MedTox LAB12463 Chromium, Serum MedTox LAB12518 Cobalt, Blood Mayo CBUR LAB12495 Cocklebur, IgE Mayo CYSQN LAB12392 Cystinuria Profile, Quantitative, 24 Hour, Urine Mayo SAM LAB12504 Entamoeba histolytica Antibody, Serum MedTox 2839 LAB12514 Ezogabine (Retigabine), POTIGA Mayo GPEP LAB12477 Green Pepper, IgE Mayo HALI LAB12478 Halibut, IgE Mayo IODU LAB12465 Iodine, Random, Urine Mayo MNU LAB12390 Manganese, 24 Hour, Urine Mayo MHRP LAB12484 Mycoplasma hominis, Molecular Detection, PCR LipoScience 600 LAB12480 NMR Lipoprofile LipoScience 630 LAB12481 NMR Lipoprofile Bostwick PCA3PLUS LAB12479 PCA3 Plus MedTox LAB12516 Sulfonylurea Screen, Qt, Serum/Plasma MedTox LAB12515 Sulfonylurea Screen, Qt, Ur Mayo URRP LAB12485 Ureaplasma species, Molecular Detection, PCR Mayo VORI LAB12475 Voriconazole, Serum Mayo BENW LAB12487 White Bean, IgE 21
22 WEBSITE CEU DVD s Available for Checkout Allina Health Laboratory sponsors quarterly continuing education presentations in the Twin Cities area. For those unable to attend, we record each presentation and make the DVD/videotapes available for viewing. Upcoming CEU event information as well as a listing of available presentations and a DVD Request Form can be found under the Continuing Education heading on our website homepage at allinahealth.org/laboratory. Thank you for choosing Allina Health Laboratory We value your business! 22
May Revised Urine Drug Screen Test Menu Effective mid-june Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory
May 2014 Lauren Anthony, MD, MT(ASCP) SBB Medical Director, Allina Health Laboratory Revised Urine Drug Test Menu Effective mid-june 2014 To better address the complexities of drug screening for different
More informationForensic Toxicology Scope of Testing and Detection Limits
Forensic Toxicology Scope of Testing and Detection Limits Table of Contents QUALITATIVE ANALYSES... 2 Volatile Screen by GC/FID... 2 Carbon Monoxide by Microdiffusion... 2 Ethylene Glycol by GC/MS... 2
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.
Drug Adherence Assessment Report Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED PRESCRIPTION FLAG ANTICIPATED
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: HYDROMORPHONE (DILAUDID, EXALGO), CYCLOBENZAPRINE (FLEXERIL), METHADONE (METHADOSE),
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG
More informationINTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY
2009 FINAL REPORT INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY This report was prepared by: Dr. Jose Arbelaez, M.D. of Baltimore Substance Abuse Systems, and Ryan J. Petteway,
More informationINTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY
INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY A report from the Office of Epidemiology and Planning Baltimore
More informationDrug Adherence Assessment Report
Prescribed Medications: Drug Adherence Assessment Report FENTANYL, OXYCODONE CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST PRESCRIPTION (S)
More informationDrugs Found in Medical Examiner Cases
s Found in Medical Examiner Cases 1,1 difluoroethane propellant in aerosols 10-Hydroxycarbazepine 11-Hydroxy Delta-9 THC 6-monoacetylmorphine 7-amino clonazepam acetaminophen acetone alpha-hydroxyalprazolam
More informationLCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching
Liquid Chromatography Mass Spectrometry SSI-LCMS-8 LCMS-8 Drugs of Abuse: Analytes with Polarity Switching LCMS-8 Summary Seventy six analytes and their internal standards are described below. Multiple
More informationAlcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082
Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending
More informationUrine Drug Testing Methods 3-5
Urine Drug Testing Methods 3-5 Type of Test Logistics Pearls Initial Screening Test: Immunoassay Confirmatory Test: Gas chromatography-mass spectrometry (GCMS) + or Liquid chromatography-mass spectrometry
More informationSeptember HCMC Toxicology Transition: Additional information and Frequently Asked Questions
September 2016 HCMC Toxicology Transition: Additional information and Frequently Asked Questions Many clinicians have asked for more information about the Urine Drug Compliance Analysis (LAB8742) switch
More information1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationLaboratory Service Report
4 05/25/19 Client C702884-DLP ROCHESTER Amphetamines, Confirmation Positive Confirmed POSITIVE by LC-S/S for the following: Amphetamine = 52 ethamphetamine = 124 ethamphetamine exists in the d- and l-isomeric
More informationPhysician s Reference for Urine and Blood Drug Testing and Interpretation
Physician s Reference for Urine and Blood Drug Testing and Interpretation DETECTIMED PANEL Urine (test code 70195) Screen Confirmation Screen Confirmation Alcohol Ethanol Amphetamines Amphetamine Methamphetamine
More information2015 Annual Physician Notice
0 Annual Physician Notice The Office of Inspector General (OIG) recommends clinical laboratories send notices to physicians and other providers who use their services, at least once a year, to inform the
More informationCDIA TM Marijuana Colloidal Gold Test Cassette (Saliva)
CDIA TM Marijuana Colloidal Gold Test Cassette (Saliva) Cat. No.: DTSJZ023 Pkg. Size: Intended Use The CDIA TM Marijuana Colloidal Gold Test Cassette (Saliva) is an immunochromatography based one step
More information1. Amphetamine (Adderall, desoxyn, Dexedrine,dextrostat, spancap, oxydess II)
Cross reactivity of various pharmaceuticals against the Drugs of Abuse Screening Panel (posted 2/3/09) The following tables are only applicable to the specific analyzer and reagents used at HRHS main lab.
More informationPain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX
Pain Management and Compliance Toxicology Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX Prescription Drug Abuse: A National Problem Prescription drug abuse is a growing
More informationnextgen precision Test Report
nextgen precision TM Test Report SUMMARY OF PRECISION S NEXTGEN TEST REPORT In an effort to provide as much clinical insight as possible to our providers, we created our comprehensive NextGen Precision
More informationThe Drug Testing Process. Employer or Practice
Disclosures Clinical Professor, Jefferson Medical College BOD MROCC [Medical Review Officer Certification Council] BOD National Sleep Foundation BOD POEMS [Pennsylvania Occupational & Environmental Medicine
More informationDynacare Laboratories
Dynacare Laboratories Affiliated with Froedtert & the Medical College of Wisconsin January 2015 2015 CPT Code Updates Dear Client: The American Medical Association (AMA) publishes the Current Procedural
More informationINTERPATH LABORATORY, INC. TEST UPDATES
EFFECTIVE DATE: February 16, 2016 INTERPATH LABORATORY, INC. TEST UPDATES Please take note of the following test updates and make the appropriate changes in your Interpath Service Manual. Feel free to
More informationRapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System
Rapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System Xiang He, 1 Casey Burrows 1, Matthew Noestheden 2, Michael Jarvis, 2 Adrian Taylor,
More informationFully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids
PO-CON1753E Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids ASMS 2017 TP-442 Joshua F. Emory 1, Nathan DeFreitas 2, Michael Roberts 1, Manoj Tyagi 2, M.
More informationRapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab
Application Note Clinical Research Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab Authors Adam Barker 1,2, Frederick G. Strathmann 3, Natalie N. Rasmussen 4, and Carrie
More informationLaboratory Testing to Support Pain Management: Methods, Concepts and Case Studies
Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Frederick G. Strathmann, PhD, DABCC, (CC,TC) Medical Director, Toxicology Associate Scientific Director of MS ARUP Laboratories
More informationToxicology Practice and Procedure Handbook
Toxicology Practice and Procedure Handbook Table of Contents Welcome Letter...3 Lab Requisition Protocol...4 Urine Collection and Shipment Protocol...5 Drug Confirmation Composite Profiles...8 Drug and
More information10/16/2017. Objectives. Drug Testing Interpretation in Addiction Care. Background. Which is Nonadherent?
Objectives Drug Testing Interpretation in Addiction Care Brandi Puet, Pharm.D. Describe the difference between immunoassay and confirmatory testing. List explanations for unexpected negative or positive
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationDrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.
Accuracy The accuracy of the DrugSmart Drugs of Abuse Tests was evaluated in comparison to commercially available drug screen tests. Sixty (60) negative urine samples collected from presumed non-user volunteers
More informationJonathan Rochon, Pier-Luc Plante, Serge Auger, Réal Paquin, Jacques Corbeil, Pierre Picard
Dried Blood Spots in Tips Targeted Drug Screening in 9 Seconds per Sample Using Laser Diode Thermal Desorption Mass Spectrometry (LDTD-MS/MS) Jonathan Rochon, Pier-Luc Plante, Serge Auger, Réal Paquin,
More informationEffective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)
1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK ccredited to Laboratory locations: Gavenny Court Brecon Road bergavenny Monmouthshire
More informationNew Test Announcements
27027 Tourney Road Valencia, CA 91355 800 421 7110 www.specialtylabs.com New Test Announcements Dear Colleague: We are pleased to announce many new test offerings this month. January 25, 2007 In oncology,
More informationFrequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up
Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up Dr. Bhushan M. Kapur Associate Professor Department of Laboratory Medicine and Pathobiology, Faculty
More informationGet Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization
Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Prepared and presented by Jennifer Bolen, JD Disclosures for Jennifer Bolen, JD Consultant - Generation
More informationUrine Opioid Dependency Panel (UODP) 1
Drug Testing Panels Urine Opioid Dependency Panel (UODP) 1 Amphetamines Amphetamine Methamphetamine Methylenedioxyamphetamine Adderall, Dexedrine, Vyvanse, Lisdexamfetamine (Speed, Bennies, Crystal Meth,
More information10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization
Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization Prepared and presented by Jennifer Bolen, JD Disclosures for Jennifer Bolen, JD Consultant - Generation
More informationUsing Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population
Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Adam S. Ptolemy 1, Colleen Murray 2, Edward Dunn 3,
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Hammersmith Medicines Research Limited Cumberland Avenue Park Royal London NW10 7EW Contact: Juan Naveda Tel: +44 (0) 20 8961 4130 Fax: +44
More informationE XCEL LENCE JUST GOT BETTER UCT FORENSICS CLEAN SCREEN XCEL SPE COLUMNS
FORENSICS UCT E XCEL LENCE JUST GOT BETTER CLEAN SCREEN XCEL SPE COLUMNS CLEAN SCREEN XCEL COLUMNS EXTRACTION OF BASIC DRUGS AND METABOLITES FROM URINE/ BLOOD USING SPE CARTRIDGES 130mg Clean Screen Xcel
More informationDetermination of 78 Banned or Controlled Racing Industry Drugs in Horse Urine Using SPE and LC-MS/MS
Determination of 78 Banned or Controlled Racing Industry Drugs in Horse Urine Using SPE and LC-MS/MS UCT Part Numbers XRDAH203 Gravity Flow XtrackT DAU 200 mg, 3 ml column SPHPHO6001-5 Select ph Buffer
More informationTherapeutic Drugs Monitoring TDM 2018 Therapeutic Drugs Monitoring Scheme Application Form
complete all sections below and return to LGC Standards Proficiency Testing by email, fax or post. Returning customer Lab ID: TM Purchase order no.: (compulsory) TDM Distribution Schedule Samples for the
More informationCentre of Forensic Sciences
Introduction Centre of Forensic Sciences Investigators and Submitters Technical Information Sheets Toxicology The performs analyses on biological samples (e.g., blood, urine, liver) to determine the absence/presence/concentration(s)
More informationPROFILE -V MEDTOXScan Drugs of Abuse Test System PACKAGE INSERT
PROFILE -V MEDTOXScan Drugs of Abuse Test System PACKAGE INSERT 1. INTENDED USE The PROFILE -V MEDTOXScan Drugs of Abuse Test System consists of the PROFILE -V MEDTOXScan Test Devices and the MEDTOXScan
More informationPrepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature. Distributed to # of Copies Distributed to # of Copies
Procedure: Status DS Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature Distributed to # of Copies Distributed to # of Copies PRINCIPLE: The Status DS 10 Panel (MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP)
More informationPROFILE -V MEDTOXScan Drugs of Abuse Test System INSERT
PROFILE -V MEDTOXScan Drugs of Abuse Test System INSERT 1. INTENDED USE The PROFILE -V MEDTOXScan Drugs of Abuse Test System consists of the PROFILE -V MEDTOXScan Test Devices and the MEDTOXScan Reader.
More informationChemaTox Blood Drug Testing Matrix (Updated May 24th, 2016)
ChemaTox Blood Drug Testing Matrix (Updated May 24th, 2016) Email: DREtox@chematox.com; Phone: (303)440-4500 Always identify any medications/drugs the suspect states they have taken, or that you suspect
More informationToxCup Drug Screen Cup Step-by Step Instructions
ToxCup Drug Screen Cup Step-by Step Instructions This is a preliminary screening test that detects drug-of-abuse in urine at specified detection levels. To confirm preliminary positive results, a more
More informationTherapeutic Drugs Monitoring TDM 2016 Therapeutic Drugs Monitoring Scheme Application Form
complete all sections below and return to LGC Standards Proficiency Testing by email, fax or post. Returning customer Lab ID: TM Purchase order no.: (compulsory) TDM Distribution Schedule Samples for the
More informationA Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography
Application Note LCMS-109 A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography Time of Flight (LC-TOF) Mass Spectrometry Introduction Many clinical
More information[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS
A Comprehensive Method for the Analysis of Pain Management Drugs and Drugs of Abuse Incorporating Simplified, Rapid Mixed-Mode SPE with UPLC-MS/MS for Clinical Research Jonathan P. Danaceau, Scott Freeto,
More informationLC Application Note. Dangerous driver?
LC Application Note Dangerous driver? www.palsystem.com Dangerous driver? Robert M. Sears 1 ; Kenneth C. Lewis 2 ; and Kim Gamble 3 1 SC Law Enforcement Division, Columbia, SC 29221; 2 OpAns LLC, Durham
More informationDRUGS OF ABUSE TEST CUPS 14-DRUG PANEL WITH ADULTERANTS Step by Step Instructions
DRUGS OF ABUSE TEST CUPS 14-DRUG PANEL WITH ADULTERANTS Step by Step Instructions For in vitro diagnostic use The McKesson Consult Drugs of Abuse Test Cup is a screening test for the rapid qualitative
More informationValidation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS
Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS Application Note Forensics Authors Jason Hudson, Ph.D., James Hutchings, Ph.D., and Rebecca Wagner, Ph.D. Virginia Department
More informationTest Definition: PCDSO Pain Clinic Drug Screen, Urine
Reporting Title: Pain Clinic Drug Screen, U Performing Location: Rochester Specimen Requirements: Collection Container/Tube: Plastic urine container Submission Container/Tube: Plastic, 60-mL urine bottle
More informationTest Definition: PDSOX Pain Clinic Drug Screen, Chain of Custody, Urine
Reporting Title: Pain Clinic Drug Screen, CoC, U Performing Location: Rochester Specimen Requirements: Container/Tube: Chain-of-Custody Kit (Supply T282) containing the specimen containers, seals, and
More informationUltra-Fast Forensic Toxicological Screening and Quantitation under 3 Minutes using SCIEX X500R QTOF System and SCIEX OS 1.
Ultra-Fast Forensic Toxicological Screening and Quantitation under 3 Minutes using SCIEX X500R QTOF System and SCIEX OS 1.0 Software Xiang He 1, Adrian M. Taylor 2, Michael Jarvis 2 and Alexandre Wang
More informationLinking Opioid Treatment in Primary Care. Roxanne Lewin M.D.
Roxanne Lewin M.D. The Facts Fewer than 10 percent of individuals with an alcohol use disorder and only about 20 percent of individuals with an opioid use disorder receive specialty treatment. Many individuals
More informationPOINT OF CARE TESTING
POINT OF CARE TESTING POINT OF CARE INSTANT TESTING Randox Testing Services offers a wide range of products to enable you to carry out on-site drug and alcohol testing for instant results. Our products
More informationEvaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.
Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K. Logan FSF Emerging Forensic Scientist Award Oral Presentation Disclosure
More informationPrescriber s Guide. Stahl s Essential Psychopharmacology
Stahl s Essential Psychopharmacology Prescriber s Guide FIFTH EDITION With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present this
More informationRetrospective Drug Use Review for the Use of Psychotropic Medications in Children
Retrospective Drug Use Review for the Use of Psychotropic Medications in Children Recommendations Send providers an annual request for additional clinical data for children receiving any of the following
More informationCross-reactivity reactivity in EMIT
Blood Drug Analysis at the State Bureau of Investigation Crime Laboratory Richard W. Waggoner, Jr. Sample Requirements 2-10 ml gray top vacutainers At least 10 ml of urine sample for drug facilitated sexual
More informationMedications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
More informationMETHAMPHETAMINE & AMPHETAMINE
METHAMPHETAMINE & AMPHETAMINE Enantiomers from Urine Rapid and Accurate Chiral Separation Polysaccharide Chiral Chiral LC LC Columns and SFC PHEN-RUO-49 Revision: Lux 3 µm AMP Column High Efficiency LC/MS/MS
More informationRapid Drug Test Cup Step-by Step Instructions
Rapid Drug Test Cup The CLIAwaived Inc. Rapid Drug Test Cup is an in vitro screening test for the rapid detection of multiple drugs in human urine at or above the following cutoff concentration: THC 11-nor-Δ9-Tetrahydrocannabinol-9-carboxylic
More informationPain Medication Management Program Monitors Patient Compliance
PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationHEDIS Resource Guide Behavioral Health
HEDIS Resource Guide Behavioral Health NA8PROGDE04232E_0000 What s Inside 1 What is HEDIS? 2 HEDIS Reference Guide for Behavioral Health 14 Behavioral Health HEDIS Measures What Is HEDIS? The Healthcare
More informationAgilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1
Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications dr. Jan Srbek, HPST Page 1 Major LC-MS Clinical Applications Steroids/Endocrinology Vitamin D Testosterone, Estradiol
More informationControlled Substance Monitoring in the Age of the Opioid Epidemic
Controlled Substance Monitoring in the Age of the Opioid Epidemic Paul E. Hilliard, MS, MD Hospital Pain Committee Chair Department of Anesthesiology CME housekeeping I have no financial disclosures AKA,
More informationPain Medication Management Program Supports Patient Outcomes and Adherence
PeaceHealth Laboratories UPDATE 2015 Revised Edition Pain Medication Management Program Supports Patient Outcomes and Adherence BENEFITS Monitors analgesic medication adherence to ensure patient safety
More informationORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS
ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA Disclaimer
More informationC O P E. Milwaukee County Opioid-Related Overdose Report MILWAUKEE COMMUNITY OPIOID PREVENTION EFFORT
Milwaukee County Opioid-Related Overdose Report 2012 2016 MILWAUKEE C O P E COMMUNITY OPIOID PREVENTION EFFORT For additional information or if you have questions about the data presented in this report,
More informationSupplementary Online Content
Supplementary Online Content Raebel MA, Newcomer SR, Reifler LM, et al. Chronic use of opioid medications before and after bariatric surgery. JAMA. doi:10.1001/jama.2013.278344 efigure. Opioid Dispensings
More informationProof of Concept for Automated SPE/HPLC/MS/MS Methods to Replace Traditional Immunoassay with MS Confirmation of Driving Under the Influence Samples
Proof of Concept for Automated SPE/HPLC/MS/MS Methods to Replace Traditional Immunoassay with MS Confirmation of Driving Under the Influence Samples Robert M. Sears, Toxicology Technical Leader 1, Kenneth
More informationDrug Adherence Assessment Report
Collection Date: 11:13 AM Gender: Female Received in Lab: 12:13 PM CT Prescribed Medications: Drug Adherence Assessment Report ACTIQ, ADDERALL, AMITRIPTYLINE, BUTRANS, CYCLOBENZAPRINE, CYMBALTA, EFFEXOR,
More informationONLINE DAT II Results matter.
From tough questions to reliable answers. ONLINE DAT II Results matter. Patient results matter Reputations are at stake: theirs and yours. Behind every Drugs-of-Abuse Test (DAT) result is a person whose
More informationMedicines Formulary BNF Section 4 Central Nervous System
Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam
More informationPayment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:
Payment Policy: Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date: Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationPowering Efficient Behavioral Health Care Services
Powering Efficient Behavioral Health Care Services Streamlining behavioral health care decisions through comprehensive and efficient drug monitoring Quest Diagnostics has you and your patients covered
More informationUrine drug testing it s not always crystal clear
Urine drug testing it s not always crystal clear Kirk Moberg, MD, PhD, FASAM Executive Medical Director, UnityPoint Health Illinois Institute for Addiction Recovery Clinical Professor of Internal Medicine
More informationEDUCATIONAL COMMENTARY rd TEST EVENT Chemistry Urine Drug Testing
EDUCATIONAL COMMENTARY 2003 3 rd TEST EVENT Chemistry Urine Drug Testing Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE
More informationSUPPLEMENTARY MATERIALS. Appendix 1. Definition of Suicidal Behavior Using ICD-9 Diagnostic Codes.
SUPPLEMENTARY MATERIALS Appendix 1. Definition of Suicidal Behavior Using ICD-9 Diagnostic Codes. For this study, suicidal behavior was defined using ICD-9 diagnostic codes and death certificates from
More informationAppendix: Psychotropic Medication Reference Tables
Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic
More informationA Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS
A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS Introduction Drug analysis from whole blood is gaining popularity due to a more complete measurement
More informationDrugs of Abuse I Serum
Drugs of Abuse I Serum 2017-11 1.10 For quality monitoring of quantitative measurements by chromatographic methods These reference materials are produced on the basis of human matrices. The highly accurate
More informationMulti-Drug Screen Test
Multi-Drug Screen Test Package Insert for OTC/CLIA-Waived- and Professional Use For in vitro diagnostic use only The Multi-Drug Screen Test offers a variety of solutions for fast and reliable drug testing
More informationValidation of an Automated Method to Remove
Shahana Wahab Huq 1, Richard Thomas 2, Agnes Cua 2, Seyed Sadjadi 1 1 Phenomenex, 411 Madrid Avenue, Torrance, CA 951 2 Precision Toxicology, 33 Bunker Hill Street, San Diego, CA 9219 Validation of an
More informationNorthSTAR. Pharmacy Manual
NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics
More informationQuantitative Drug Testing Workgroup Notice (New, Revised and Deleted Codes for 2015)
The following table is a listing of the new, revised, and deleted codes in the Drug Testing, Therapeutic Drug Assay, and Chemistry sections that will be effective January 1, 2015. If an applicant or other
More informationToxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey
Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey Kayla J. Lowrie, MS, Jennifer Turri, BS, Jill Yeakel, MSFS, Barry K. Logan, PhD, DABFT, Arcadia University, 450 S. Easton
More informationPROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN
PROJECT ECHO OPIOID USE DISORDER IN PREGNANT WOMEN 1 OPIOID USE DISORDER IN WOMEN Recognition & Prevention Date: August 14 th, Time: 8 am Presenters: Deepa Nagar MD, Andria Peterson PharmD Maternal Treatment
More informationPROFILE -IV VISUAL PRODUCT INSERT
PROFILE -IV VISUAL PRODUCT INSERT The PROFILE -IV VISUAL products are one-step qualitative screening assays for the detection of one or more of the following: Amphetamines, Barbiturates, Benzodiazepines,
More informationOne Step Multi-Drug Urine T-Cup
One Step Multi-Drug Urine T-Cup offers any combination from 2 to 16 drugs of abuse tests for 16 different drugs: Amphetamine (AMP), Barbiturates (BAR), Benzodiazepines (BZO), Cocaine (COC), Marijuana (THC),
More informationOregon Health & Science University Department of Pathology, Division of Laboratory Medicine Core Laboratory
Oregon Health & Science University Department of Pathology, Division of Laboratory Medicine Core Laboratory Summary of s that may be detected by OHSU Drugs of Abuse Screening Methods Amphetamine/Methamphetamine
More informationZCPT S. Jog Rd. Suite Greenacres, FL Phone: (561)
ZCPT 4300 S. Jog Rd. Suite 540171 Greenacres, FL 33454 : (561) 343-0789 : ZCPT@ZCLabServices.com Official Use Only Client ID: Toxicology Proficiency Testing Order Form Institution Name (Please Print) CLIA
More information